Hidradenitis Suppurativa
📧 Sign up to get email alerts when something new happens for Hidradenitis Suppurativa.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-12-17Clinical Trial Update: Efficacy and Tolerability of a Fractional Ablative Erbium Laser for Axillary Scarring for Hidradenitis Suppurativa Patients [NA]
A clinical trial evaluating the efficacy and tolerability of fractional ablative Erbium laser for axillary scarring in hidradenitis suppurat…
-
CLINICAL_TRIALS withdrawal · 2025-12-16Clinical Trial Update: Botulinum Toxin-A for Hidradenitis Suppurativa [Phase 4]
A Phase 4 clinical trial of botulinum toxin A for hidradenitis suppurativa has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-09-04Clinical Trial Update: Gentian Violet Treatment for Hidradenitis Suppurativa [Phase 2]
A Phase 2 trial evaluating Gentian Violet for hidradenitis suppurativa has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Spironolactone for Hidradenitis Suppurativa [Phase 4]
A Phase 4 clinical trial evaluating spironolactone for hidradenitis suppurativa has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2022-09-29Clinical Trial Update: Hidradenitis Suppurativa Patient Experience With Humira Treatment [Phase 4]
A Phase 4 clinical trial assessing Humira for hidradenitis suppurativa has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2021-01-29EMA Withdrawn: Halimatoz (adalimumab) — Sandoz GmbH
The EMA withdrew Halimatoz (adalimumab) supplied by Sandoz GmbH from the market.
-
EMA withdrawal · 2019-03-06EMA Withdrawn: Cyltezo (adalimumab) — Boehringer Ingelheim International GmbH
The EMA withdrew Cyltezo (adalimumab) from Boehringer Ingelheim International GmbH, affecting multiple indications including hidradenitis su…
-
EMA withdrawal · 2019-03-05EMA Withdrawn: Solymbic (adalimumab) — Amgen Europe B.V.
Solymbic (adalimumab) has been withdrawn from the market by Amgen Europe B.V.